Susquehanna International Group, LLP Uro Gen Pharma Ltd. Call Options Transaction History

Susquehanna International Group, LLP

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$12.7 - $17.92 $600,710 - $847,616	-47,300 Reduced 79.5%	12,200 $154,000
Q2 2024 Aug 15, 2024	BUY	$12.72 - $19.2 $445,200 - $672,000	35,000 Added 142.86%	59,500 $998,000
Q1 2024 May 07, 2024	BUY	$13.81 - $19.33 $338,345 - $473,584	24,500 New	24,500 $367,000
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $122,876 - $314,696	13,900 New	13,900 $194,000
Q1 2023 May 16, 2023	SELL	$7.99 - $11.02 $59,126 - $81,548	-7,400 Reduced 17.25%	35,500 $328,000
Q4 2022 Feb 14, 2023	BUY	$7.55 - $11.96 $161,570 - $255,944	21,400 Added 99.53%	42,900 $380,000
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.41 $155,015 - $202,315	21,500 New	21,500 $179,000
Q3 2020 Nov 16, 2020	SELL	$18.81 - $26.42 $223,838 - $314,398	-11,900 Reduced 31.82%	25,500 $492,000
Q2 2020 Aug 14, 2020	SELL	$16.5 - $29.7 $1.44 Million - $2.59 Million	-87,100 Reduced 69.96%	37,400 $977,000
Q1 2020 May 15, 2020	BUY	$13.68 - $34.6 $342,000 - $865,000	25,000 Added 25.13%	124,500 $2.22 Million
Q4 2019 Feb 14, 2020	BUY	$21.11 - $34.86 $1.05 Million - $1.74 Million	49,900 Added 100.6%	99,500 $3.32 Million
Q3 2019 Nov 14, 2019	BUY	$23.83 - $36.44 $226,384 - $346,180	9,500 Added 23.69%	49,600 $1.18 Million
Q2 2019 Aug 14, 2019	BUY	$32.75 - $40.35 $88,425 - $108,945	2,700 Added 7.22%	40,100 $1.44 Million
Q1 2019 May 15, 2019	BUY	$35.47 - $54.55 $1.04 Million - $1.6 Million	29,400 Added 367.5%	37,400 $1.38 Million
Q4 2018 Feb 14, 2019	BUY	$38.35 - $50.39 $306,800 - $403,120	8,000 New	8,000 $344,000

130

35.9M

22K

93.8K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $254M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.